A new study has shown a novel peptide antagonist, given in combination with a PD-1 inhibitor, to be safe and well-tolerated in patients with advanced, refractory pancreatic and rectal cancer.
The highest dose tested had a good safety profile and was recommended for use in future patient trials, as reported in Journal of Pancreatic Cancer, a peer-reviewed open access publication from Mary Ann Liebert, Inc., publishers. Read more . . .